rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2023-658-666rsp-3471Research ArticleПРОГРЕСС В РЕВМАТОЛОГИИ В XXI ВЕКЕPROGRESS IN RHEUMATOLOGY IN THE XXI CENTURYБлокада сигнального пути интерлейкина 6 при ревматоидном артрите: влияние на ожирение, адипоцитокины и метаболизм глюкозыBlockade of the interleukin-6 signaling pathway in rheumatoid arthritis: Effects on obesity, adipocytokines and glucose metabolismhttps://orcid.org/0000-0003-1147-5936КондратьеваЛ. В.KondratyevaL. V.

Кондратьева Любовь Валерьевна – к.м.н., старший научный сотрудник лаборатории системной красной волчанки ФГБНУ «НИИР им В.А. Насоновой».

115522, Москва, Каширское шоссе, 34а

Liubov V. Kondratyeva.

115522, Moscow, Kashirskoye Highway, 34A

kondratyeva.liubov@yandex.ruhttps://orcid.org/0000-0002-2024-6927ГорбуноваЮ. Н.GorbunovaYu. S.

К.м.н., научный сотрудник лаборатории системной красной волчанки ФГБНУ «НИИР им В.А. Насоновой».

115522, Москва, Каширское шоссе, 34а

Yulia S. Gorbunova.

115522, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0001-5793-4689ПопковаТ. В.PopkovaT. V.

Д.м.н., заведующий лабораторией системной красной волчанки, начальник отдела системных ревматических заболеваний ФГБНУ «НИИР им В.А. Насоновой».

115522, Москва, Каширское шоссе, 34а

Tatiana V. Popkova.

115522, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0002-1598-8360НасоновЕ. Л.NasonovE. L.

Д.м.н., профессор, академик РАН, научный руководитель ФГБНУ «НИИР им В.А. Насоновой»; профессор кафедры внутренних, профессиональных болезней и ревматологии ФГАОУ ВО «ПМГМУ им. И.М. Сеченова» Минздрава России (Сеченовский Университет).

115522, Москва, Каширское шоссе, 34а; 119991, Москва, ул. Трубецкая, 8, стр. 2

Evgeny L. Nasonov.

115522, Moscow, Kashirskoye Highway, 34A; 119991, Moscow, Trubetskaya str., 8, building 2

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияV.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University of the Ministry of Health Care of Russian Federation (Sechenov University)Russian Federation202331122023616658666Copyright © Кондратьева Л.В., Горбунова Ю.Н., Попкова Т.В., Насонов Е.Л., 20242024Кондратьева Л.В., Горбунова Ю.Н., Попкова Т.В., Насонов Е.Л.Kondratyeva L.V., Gorbunova Y.S., Popkova T.V., Nasonov E.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3471

Интерлейкин (ИЛ) 6 – один из ключевых цитокинов, роль которого в развитии воспаления при ревматоидном артрите (РА) хорошо доказана. Гораздо хуже изучены плейотропные эффекты самого цитокина и генно-инженерных препаратов (ГИБП), ингибирующих его биологическое действие. В обзоре представлены сведения о воздействии ИЛ-6 и ГИБП, блокирующих его сигнальный путь, на жировую ткань, метаболизм глюкозы и уровень адипоцитокинов при РА. Показано, что длительная блокада рецепторов ИЛ-6 не приводит к накоплению жировой ткани и улучшает контроль гликемии, хотя не ясно, связан ли подобный эффект только с противовоспалительными свойствами тоцилизумаба и сарилумаба. Более того, до конца не понятен механизм такого благоприятного действия, поскольку данные о повышении чувствительности периферических тканей к инсулину на фоне терапии тоцилизумабом неоднозначны. Возможно, определенную роль играют изменения взаимоотношений адипоцитокинов или гормонов.

Interleukin (IL) 6 is one of the key cytokines whose role in the inflammation development in rheumatoid arthritis (RA), is well proven. The pleiotropic effects of the cytokine and biologic agents that inhibit its action have been studied much worse. The review provides information on the effects of IL-6 and blocking its signaling pathway on adipose tissue, glucose metabolism and adipocytokine levels in RA. It has been shown that prolonged blockade of IL-6 receptors does not lead to the adipose tissue accumulation and improves glycemic control, although it is not clear whether such effect is associated only with the anti-inflammatory properties of tocilizumab and sarilumab. Moreover, the mechanism of this beneficial effect is not fully understood, since the data on increased sensitivity of peripheral tissues to insulin during tocilizumab treatment are ambiguous. Perhaps changes in the relationship of adipocytokines or hormones play a certain role.

интерлейкин 6тоцилизумабсарилумабожирениеадипоцитокиныадипонектинлептинрезистинвисфатининсулинорезистентностьсахарный диабетгликированный гемоглобинinterleukin 6tocilizumabsarilumabobesityadipocytokinesadiponectinleptinresistinvisfatininsulin resistancediabetes mellitusglycated hemoglobinСтатья подготовлена в рамках научно-исследовательской работы ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», № государственного задания PK 123041800015-7.ReferencesНасонов ЕЛ, Файст Е. Перспективы ингибиции интерлейкина-6 при ревматоидном артрите: олокизумаб (новые моноклональные антитела к ИЛ-6). Научно-практическая ревматология. 2022;60(5):505-518. doi: 10.47360/1995-4484-2022-505-518Nasonov EL, Feist E. The prospects of interleukin-6 inhibition in rheumatoid arthritis: Olokizumab (novel monoclonal antibodies to IL-6). Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2022;60(5):505-518 (In Russ.). doi: 10.47360/1995-4484-2022-505-518Попкова ТВ, Новиков ДС, Насонов ЕЛ. Интерлейкин 6 и сердечно-сосудистая патология при ревматоидном артрите. Научно-практическая ревматология. 2011;49(4):64-72. doi: 10.14412/1995-4484-2011-63Popkova TV, Novikov DS, Nasonov EL. Interleukin 6 and cardiovascular pathology for rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2011;49(4):64-72 (In Russ.). doi: 10.14412/1995-4484-2011-63Удачкина ЕВ, Новикова ДС, Попкова ТВ, Насонов ЕЛ. Роль интерлейкина 6 в развитии атеросклероза при ревматоидном артрите. Современная ревматология. 2013;7(3):25-32. doi: 10.14412/1996-7012-2013-7Udachkina EV, Novikova DS, Popkova TV, Nasonov EL. Role of interleukin-6 in the development of atherosclerosis in rheumatoid arthritis. Modern Rheumatology Journal. 2013;7(3):25-32 (In Russ.). doi: 10.14412/1996-7012-2013-7Герасимова ЕВ, Попкова ТВ, Мартынова АВ, Кириллова ИГ, Маркелова ЕИ, Семашко АС, и др. Динамика традиционных модифицируемых факторов риска, суммарного сердечно-сосудистого риска и структурных изменений сонных артерий у больных ревматоидным артритом на фоне длительной терапии ингибитором рецепторов интерлейкина-6. Научно-практическая ревматология. 2021;59(1):84-92. doi: 10.47360/1995-4484-2021-84-92Gerasimova EV, Popkova TV, Martynova AV, Kirillova IG, Markelova EI, Semashko AS, et al. Dynamics of traditional modifiable risk factors, total cardiovascular risk, and structural changes of carotid arteries in patients with rheumatoid arthritis on long-term interleukin-6 receptor antagonist treatment. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(1):84-92 (In Russ.). doi: 10.47360/1995-4484-2021-84-92Гордеев АВ, Галушко ЕА, Савушкина НМ, Демидова НВ, Семашко АС. Оценка мультиморбидного профиля (CIRS) при ревматоидном артрите. Первые результаты. Современная ревматология. 2019;13(3):10-16. doi: 10/14412/1996-7012-2019-3-10-16Gordeev AV, Galushko EA, Savushkina NM, Demidova NV, Semashko AS. Assessing the multimorbid profile (CIRS) in rheumatoid arthritis. First results. Modern Rheumatology Journal. 2019;13(3):10-16 (In Russ.). doi: 10/14412/1996-7012-2019-3-10-16Hoene M, Weigert C. The role of interleukin-6 in insulin resistance, body fat distribution and energy balance. Obes Rev. 2008;9(1):20-29. doi: 10.1111/j.1467-789X.2007.00410.xHoene M, Weigert C. The role of interleukin-6 in insulin resistance, body fat distribution and energy balance. Obes Rev. 2008;9(1):20-29. doi: 10.1111/j.1467-789X.2007.00410.xLagathu C, Bastard JP, Auclair M, Maachi M, Capeau J, Caron M. Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: Prevention by rosiglitazone. Biochem Biophys Res Commun. 2003;311(2):372-379. doi: 10.1016/j.bbrc.2003.10.013Lagathu C, Bastard JP, Auclair M, Maachi M, Capeau J, Caron M. Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: Prevention by rosiglitazone. Biochem Biophys Res Commun. 2003;311(2):372-379. doi: 10.1016/j.bbrc.2003.10.013Klover PJ, Zimmers TA, Koniaris LG, Mooney RA. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes. 2003;52(11):2784-2789. doi: 10.2337/diabetes.52.11.2784Klover PJ, Zimmers TA, Koniaris LG, Mooney RA. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes. 2003;52(11):2784-2789. doi: 10.2337/diabetes.52.11.2784Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulinresistant subjects. J Biol Chem. 2003;278(46):45777-45784. doi: 10.1074/jbc.M301977200Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulinresistant subjects. J Biol Chem. 2003;278(46):45777-45784. doi: 10.1074/jbc.M301977200Spranger J, Kroke A, Möhlig M, Hoffmann K, Bergmann MM, Ristow M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: Results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes. 2003;52(3):812-817. doi: 10.2337/diabetes.52.3.812Spranger J, Kroke A, Möhlig M, Hoffmann K, Bergmann MM, Ristow M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: Results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes. 2003;52(3):812-817. doi: 10.2337/diabetes.52.3.812Климонтов ВВ, Тян НВ, Фазуллина ОН, Мякина НЕ, Орлов НБ. Коненков ВИ. Белки острой фазы воспаления и адипоцитокины в сыворотке крови у женщин с сахарным диабетом 2-го типа: взаимосвязи с составом тела и колебаниями уровня глюкозы в крови. Терапевтический архив. 2016;88(10):35-41. doi: 10.17116/terarkh2016881035-41Klimontov VV, Tyan NV, Fazullina ON, Myakina NE, Orlov NB, Konenkov VI. Acute-phase serum proteins and adipocytokines in women with type 2 diabetes mellitus: Relationships with body composition and blood glucose fluctuations. Terapevticheskii arkhiv. 2016;88(10):35-41 (In Russ.). doi: 10.17116/terarkh2016881035-41Carey AL, Bruce CR, Sacchetti M, Anderson MJ, Olsen DB, Saltin B, et al. Interleukin-6 and tumor necrosis factor-alpha are not increased in patients with Type 2 diabetes: evidence that plasma interleukin-6 is related to fat mass and not insulin responsiveness. Diabetologia. 2004;47(6):1029-1037. doi: 10.1007/s00125-004-1403-xCarey AL, Bruce CR, Sacchetti M, Anderson MJ, Olsen DB, Saltin B, et al. Interleukin-6 and tumor necrosis factor-alpha are not increased in patients with Type 2 diabetes: evidence that plasma interleukin-6 is related to fat mass and not insulin responsiveness. Diabetologia. 2004;47(6):1029-1037. doi: 10.1007/s00125-004-1403-xKopp HP, Kopp CW, Festa A, Krzyzanowska K, Kriwanek S, Minar E, et al. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol. 2003;23(6): 1042-1047. doi: 10.1161/01.ATV.0000073313.16135.21Kopp HP, Kopp CW, Festa A, Krzyzanowska K, Kriwanek S, Minar E, et al. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol. 2003;23(6): 1042-1047. doi: 10.1161/01.ATV.0000073313.16135.21Rehman K, Akash MSH, Liaqat A, Kamal S, Qadir MI, Rasul A. Role of Interleukin-6 in development of insulin resistance and type 2 diabetes mellitus. Crit Rev Eukaryot Gene Expr. 2017;27(3):229-236. doi: 10.1615/CritRevEukaryotGeneExpr.2017019712Rehman K, Akash MSH, Liaqat A, Kamal S, Qadir MI, Rasul A. Role of Interleukin-6 in development of insulin resistance and type 2 diabetes mellitus. Crit Rev Eukaryot Gene Expr. 2017;27(3):229-236. doi: 10.1615/CritRevEukaryotGeneExpr.2017019712Jin H, Ning Y, Zhou H, Wang Y. IL-6 promotes islet β-cell dysfunction in rat collagen-induced arthritis. J Diabetes Res. 2016;2016:7592931. doi: 10.1155/2016/7592931Jin H, Ning Y, Zhou H, Wang Y. IL-6 promotes islet β-cell dysfunction in rat collagen-induced arthritis. J Diabetes Res. 2016;2016:7592931. doi: 10.1155/2016/7592931Oh YS, Lee YJ, Park EY, Jun HS. Interleukin-6 treatment induces beta-cell apoptosis via STAT-3-mediated nitric oxide production. Diabetes Metab Res Rev. 2011;27(8):813-819. doi: 10.1002/dmrr.1233Oh YS, Lee YJ, Park EY, Jun HS. Interleukin-6 treatment induces beta-cell apoptosis via STAT-3-mediated nitric oxide production. Diabetes Metab Res Rev. 2011;27(8):813-819. doi: 10.1002/dmrr.1233Marasco MR, Conteh AM, Reissaus CA, Cupit JE 5th, Appleman EM, Mirmira RG, et al. Interleukin-6 reduces β-cell oxidative stress by linking autophagy with the antioxidant response. Diabetes. 2018;67(8):1576-1588. doi: 10.2337/db17-1280Marasco MR, Conteh AM, Reissaus CA, Cupit JE 5th, Appleman EM, Mirmira RG, et al. Interleukin-6 reduces β-cell oxidative stress by linking autophagy with the antioxidant response. Diabetes. 2018;67(8):1576-1588. doi: 10.2337/db17-1280Rajendran S, Anquetil F, Quesada-Masachs E, Graef M, Gonzalez N, McArdle S, et al. IL-6 is present in beta and alpha cells in human pancreatic islets: Expression is reduced in subjects with type 1 diabetes. Clin Immunol. 2020;211:108320. doi: 10.1016/j.clim.2019.108320Rajendran S, Anquetil F, Quesada-Masachs E, Graef M, Gonzalez N, McArdle S, et al. IL-6 is present in beta and alpha cells in human pancreatic islets: Expression is reduced in subjects with type 1 diabetes. Clin Immunol. 2020;211:108320. doi: 10.1016/j.clim.2019.108320Pedersen BK, Febbraio MA. Point: Interleukin-6 does have a beneficial role in insulin sensitivity and glucose homeostasis. J Appl Physiol (1985). 2007;102(2):814-816. doi: 10.1152/japplphysiol.01208.2006Pedersen BK, Febbraio MA. Point: Interleukin-6 does have a beneficial role in insulin sensitivity and glucose homeostasis. J Appl Physiol (1985). 2007;102(2):814-816. doi: 10.1152/japplphysiol.01208.2006Ellingsgaard H, Hauselmann I, Schuler B, Habib AM, Baggio LL, Meier DT, et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med. 2011;17(11):1481-1489. doi: 10.1038/nm.2513Ellingsgaard H, Hauselmann I, Schuler B, Habib AM, Baggio LL, Meier DT, et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med. 2011;17(11):1481-1489. doi: 10.1038/nm.2513Hunschede S, Kubant R, Akilen R, Thomas S, Anderson GH. Decreased appetite after high-intensity exercise correlates with increased plasma interleukin-6 in normal-weight and overweight/obese boys. Curr Dev Nutr. 2017;1(3):e000398. doi: 10.3945/cdn.116.000398Hunschede S, Kubant R, Akilen R, Thomas S, Anderson GH. Decreased appetite after high-intensity exercise correlates with increased plasma interleukin-6 in normal-weight and overweight/obese boys. Curr Dev Nutr. 2017;1(3):e000398. doi: 10.3945/cdn.116.000398Patsalos O, Dalton B, Himmerich H. Effects of IL-6 signaling pathway inhibition on weight and BMI: A systematic review and meta-analysis. Int J Mol Sci. 2020;21(17):6290. doi: 10.3390/ijms21176290Patsalos O, Dalton B, Himmerich H. Effects of IL-6 signaling pathway inhibition on weight and BMI: A systematic review and meta-analysis. Int J Mol Sci. 2020;21(17):6290. doi: 10.3390/ijms21176290Wallenius V, Wallenius K, Ahrén B, Rudling M, Carlsten H, Dickson SL, et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med. 2002;8(1):75-79. doi: 10.1038/nm0102-75Wallenius V, Wallenius K, Ahrén B, Rudling M, Carlsten H, Dickson SL, et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med. 2002;8(1):75-79. doi: 10.1038/nm0102-75Di Gregorio GB, Hensley L, Lu T, Ranganathan G, Kern PA. Lipid and carbohydrate metabolism in mice with a targeted mutation in the IL-6 gene: Absence of development of age-related obesity. Am J Physiol Endocrinol Metab. 2004;287(1):E182-E187. doi: 10.1152/ajpendo.00189.2003Di Gregorio GB, Hensley L, Lu T, Ranganathan G, Kern PA. Lipid and carbohydrate metabolism in mice with a targeted mutation in the IL-6 gene: Absence of development of age-related obesity. Am J Physiol Endocrinol Metab. 2004;287(1):E182-E187. doi: 10.1152/ajpendo.00189.2003Lyngsø D, Simonsen L, Bülow J. Metabolic effects of interleukin-6 in human splanchnic and adipose tissue. J Physiol. 2002;543(Pt 1):379-386. doi: 10.1113/jphysiol.2002.021022Lyngsø D, Simonsen L, Bülow J. Metabolic effects of interleukin-6 in human splanchnic and adipose tissue. J Physiol. 2002;543(Pt 1):379-386. doi: 10.1113/jphysiol.2002.021022van Hall G, Steensberg A, Sacchetti M, Fischer C, Keller C, Schjerling P, et al. Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab. 2003;88(7):3005-3010. doi: 10.1210/jc.2002-021687van Hall G, Steensberg A, Sacchetti M, Fischer C, Keller C, Schjerling P, et al. Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab. 2003;88(7):3005-3010. doi: 10.1210/jc.2002-021687Hansen D, Dendale P, Beelen M, Jonkers RA, Mullens A, Corluy L, et al. Plasma adipokine and inflammatory marker concentrations are altered in obese, as opposed to non-obese, type 2 diabetes patients. Eur J Appl Physiol. 2010;109(3):397-404. doi: 10.1007/s00421-010-1362-5Hansen D, Dendale P, Beelen M, Jonkers RA, Mullens A, Corluy L, et al. Plasma adipokine and inflammatory marker concentrations are altered in obese, as opposed to non-obese, type 2 diabetes patients. Eur J Appl Physiol. 2010;109(3):397-404. doi: 10.1007/s00421-010-1362-5Pang Y, Kartsonaki C, Lv J, Fairhurst-Hunter Z, Millwood IY, Yu C, et al. Associations of adiposity, circulating protein biomarkers, and risk of major vascular diseases. JAMA Cardiol. 2021;6(3):276-286. doi: 10.1001/jamacardio.2020.6041Pang Y, Kartsonaki C, Lv J, Fairhurst-Hunter Z, Millwood IY, Yu C, et al. Associations of adiposity, circulating protein biomarkers, and risk of major vascular diseases. JAMA Cardiol. 2021;6(3):276-286. doi: 10.1001/jamacardio.2020.6041Schultz O, Oberhauser F, Saech J, Rubbert-Roth A, Hahn M, Krone W, et al. Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PLoS One. 2010;5(12):e14328. doi: 10.1371/journal.pone.0014328Schultz O, Oberhauser F, Saech J, Rubbert-Roth A, Hahn M, Krone W, et al. Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PLoS One. 2010;5(12):e14328. doi: 10.1371/journal.pone.0014328Hoffman E, Rahat MA, Feld J, Elias M, Rosner I, Kaly L, et al. Effects of tocilizumab, an anti-interleukin-6 receptor antibody, on serum lipid and adipokine levels in patients with rheumatoid arthritis. Int J Mol Sci. 2019;20(18):4633. doi: 10.3390/ijms20184633Hoffman E, Rahat MA, Feld J, Elias M, Rosner I, Kaly L, et al. Effects of tocilizumab, an anti-interleukin-6 receptor antibody, on serum lipid and adipokine levels in patients with rheumatoid arthritis. Int J Mol Sci. 2019;20(18):4633. doi: 10.3390/ijms20184633Lurati A, Laria A, Mazzocchi D, Re KA, Marrazza MG, Faggioli PM, et al. Improvement of HbA1c in patients with type 2 diabetes mellitus and rheumatoid arthritis treated with bDMARDs. Open Access Rheumatol. 2021;13:73-78. doi: 10.2147/OARRR.S302679Lurati A, Laria A, Mazzocchi D, Re KA, Marrazza MG, Faggioli PM, et al. Improvement of HbA1c in patients with type 2 diabetes mellitus and rheumatoid arthritis treated with bDMARDs. Open Access Rheumatol. 2021;13:73-78. doi: 10.2147/OARRR.S302679Ferraz-Amaro I, Hernández-Hernández MV, Tejera-Segura B, Delgado-Frías E, Macía-Díaz M, et al. Effect of IL-6 receptor blockade on proprotein convertase subtilisin/kexin type-9 and cholesterol efflux capacity in rheumatoid arthritis patients. Horm Metab Res. 2019;51(3):200-209. doi: 10.1055/a-0833-4627Ferraz-Amaro I, Hernández-Hernández MV, Tejera-Segura B, Delgado-Frías E, Macía-Díaz M, et al. Effect of IL-6 receptor blockade on proprotein convertase subtilisin/kexin type-9 and cholesterol efflux capacity in rheumatoid arthritis patients. Horm Metab Res. 2019;51(3):200-209. doi: 10.1055/a-0833-4627Fioravanti A, Tenti S, Bacarelli MR, Damiani A, Li Gobbi F, Bandinelli F, et al. Tocilizumab modulates serum levels of adiponectin and chemerin in patients with rheumatoid arthritis: Potential cardiovascular protective role of IL-6 inhibition. Clin Exp Rheumatol. 2019;37(2):293-300.Fioravanti A, Tenti S, Bacarelli MR, Damiani A, Li Gobbi F, Bandinelli F, et al. Tocilizumab modulates serum levels of adiponectin and chemerin in patients with rheumatoid arthritis: Potential cardiovascular protective role of IL-6 inhibition. Clin Exp Rheumatol. 2019;37(2):293-300.Pappas DA, Etzel CJ, Crabtree M, Blachley T, Best J, Zlotnick S, et al. Effectiveness of tocilizumab in patients with rheumatoid arthritis is unaffected by comorbidity burden or obesity: Data from a US registry. J Rheumatol. 2020;47(10):1464-1474. doi: 10.3899/jrheum.190282Pappas DA, Etzel CJ, Crabtree M, Blachley T, Best J, Zlotnick S, et al. Effectiveness of tocilizumab in patients with rheumatoid arthritis is unaffected by comorbidity burden or obesity: Data from a US registry. J Rheumatol. 2020;47(10):1464-1474. doi: 10.3899/jrheum.190282Hugo M, Pierreisnard A, Mehsen-Cetre N, Gin H, Schaeverbeke T, Rigalleau V. Action of tocilizumab on energy expenditure in rheumatoid arthritis: A prospective study using calorimetry and actimetry. Joint Bone Spine. 2017;84(6):751-752. doi: 10.1016/j.jbspin.2016.11.011Hugo M, Pierreisnard A, Mehsen-Cetre N, Gin H, Schaeverbeke T, Rigalleau V. Action of tocilizumab on energy expenditure in rheumatoid arthritis: A prospective study using calorimetry and actimetry. Joint Bone Spine. 2017;84(6):751-752. doi: 10.1016/j.jbspin.2016.11.011Tournadre A, Pereira B, Dutheil F, Giraud C, Courteix D, Sapin V, et al. Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis. J Cachexia Sarcopenia Muscle. 2017;8(4):639-646. doi: 10.1002/jcsm.12189Tournadre A, Pereira B, Dutheil F, Giraud C, Courteix D, Sapin V, et al. Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis. J Cachexia Sarcopenia Muscle. 2017;8(4):639-646. doi: 10.1002/jcsm.12189Toussirot E, Marotte H, Mulleman D, Cormier G, Coury F, Gaudin P, et al. Increased high molecular weight adiponectin and lean mass during tocilizumab treatment in patients with rheumatoid arthritis: A 12-month multicentre study. Arthritis Res Ther. 2020;22(1):224. doi: 10.1186/s13075-020-02297-7Toussirot E, Marotte H, Mulleman D, Cormier G, Coury F, Gaudin P, et al. Increased high molecular weight adiponectin and lean mass during tocilizumab treatment in patients with rheumatoid arthritis: A 12-month multicentre study. Arthritis Res Ther. 2020;22(1):224. doi: 10.1186/s13075-020-02297-7Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS Lett. 2006;580(12):2917-2921. doi: 10.1016/j.febslet.2006.04.028Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS Lett. 2006;580(12):2917-2921. doi: 10.1016/j.febslet.2006.04.028Laurberg TB, Frystyk J, Ellingsen T, Hansen IT, Jørgensen A, Tarp U, et al. Plasma adiponectin in patients with active, early, and chronic rheumatoid arthritis who are steroid-and disease-modifying antirheumatic drug-naive compared with patients with osteoarthritis and controls. J Rheumatol. 2009;36(9):1885-1891. doi: 10.3899/jrheum.080907Laurberg TB, Frystyk J, Ellingsen T, Hansen IT, Jørgensen A, Tarp U, et al. Plasma adiponectin in patients with active, early, and chronic rheumatoid arthritis who are steroid-and disease-modifying antirheumatic drug-naive compared with patients with osteoarthritis and controls. J Rheumatol. 2009;36(9):1885-1891. doi: 10.3899/jrheum.080907Toussirot E. The influence of adipokines on radiographic damage in inflammatory rheumatic diseases. Biomedicines. 2023;11(2):536. doi: 10.3390/biomedicines11020536Toussirot E. The influence of adipokines on radiographic damage in inflammatory rheumatic diseases. Biomedicines. 2023;11(2):536. doi: 10.3390/biomedicines11020536Chen X, Wang K, Lu T, Wang J, Zhou T, Tian J, et al. Adiponectin is negatively associated with disease activity and Sharp score in treatment-naïve Han Chinese rheumatoid arthritis patients. Sci Rep. 2022;12(1):2092. doi: 10.1038/s41598-022-06115-9Chen X, Wang K, Lu T, Wang J, Zhou T, Tian J, et al. Adiponectin is negatively associated with disease activity and Sharp score in treatment-naïve Han Chinese rheumatoid arthritis patients. Sci Rep. 2022;12(1):2092. doi: 10.1038/s41598-022-06115-9Giles JT, van der Heijde DM, Bathon JM. Association of circulating adiponectin levels with progression of radiographic joint destruction in rheumatoid arthritis. Ann Rheum Dis. 2011;70(9):1562-1568.Giles JT, van der Heijde DM, Bathon JM. Association of circulating adiponectin levels with progression of radiographic joint destruction in rheumatoid arthritis. Ann Rheum Dis. 2011;70(9):1562-1568.Federico LE, Johnson TM, England BR, Wysham KD, George MD, Sauer B, et al. Circulating adipokines and associations with incident cardiovascular disease in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2023;75(4):768-777. doi: 10.1002/acr.24885Federico LE, Johnson TM, England BR, Wysham KD, George MD, Sauer B, et al. Circulating adipokines and associations with incident cardiovascular disease in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2023;75(4):768-777. doi: 10.1002/acr.24885Baker JF, England BR, George MD, Wysham K, Johnson T, Kunkel G, et al. Elevations in adipocytokines and mortality in rheumatoid arthritis. Rheumatology (Oxford). 2022;61(12):4924-4934. doi: 10.1093/rheumatology/keac191Baker JF, England BR, George MD, Wysham K, Johnson T, Kunkel G, et al. Elevations in adipocytokines and mortality in rheumatoid arthritis. Rheumatology (Oxford). 2022;61(12):4924-4934. doi: 10.1093/rheumatology/keac191Маркова ТН, Мищенко НК, Петина ДВ. Адипоцитокины: современный взгляд на дефиницию, классификацию и роль в организме. Проблемы эндокринологии. 2022;68(1):73-80. doi: 10.14341/probl12805Markova TN, Mishchenko NK, Petina DV. Adipocytokines: Modern definition, classification and physiological role. Problems of Endocrinology. 2022;68(1):73-80 (In Russ.). doi: 10.14341/probl12805Ait Eldjoudi D, Cordero Barreal A, Gonzalez-Rodríguez M, Ruiz-Fernández C, Farrag Y, Farrag M, et al. Leptin in osteoarthritis and rheumatoid arthritis: Player or bystander? Int J Mol Sci. 2022;23(5):2859. doi: 10.3390/ijms23052859Ait Eldjoudi D, Cordero Barreal A, Gonzalez-Rodríguez M, Ruiz-Fernández C, Farrag Y, Farrag M, et al. Leptin in osteoarthritis and rheumatoid arthritis: Player or bystander? Int J Mol Sci. 2022;23(5):2859. doi: 10.3390/ijms23052859Wueest S, Seelig E, Timper K, Lyngbaek MP, Karstoft K, Donath MY, et al. IL-6 receptor blockade increases circulating adiponectin levels in people with obesity: An explanatory analysis. metabolites. 2021;11(2):79. doi: 10.3390/metabo11020079Wueest S, Seelig E, Timper K, Lyngbaek MP, Karstoft K, Donath MY, et al. IL-6 receptor blockade increases circulating adiponectin levels in people with obesity: An explanatory analysis. metabolites. 2021;11(2):79. doi: 10.3390/metabo11020079Pulito-Cueto V, Remuzgo-Martínez S, Genre F, Calvo-Alén J, Aurrecoechea E, Llorente I, et al. Anti-IL-6 therapy reduces leptin serum levels in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2020;38(6):1201-1205.Pulito-Cueto V, Remuzgo-Martínez S, Genre F, Calvo-Alén J, Aurrecoechea E, Llorente I, et al. Anti-IL-6 therapy reduces leptin serum levels in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2020;38(6):1201-1205.Pulito-Cueto V, Remuzgo-Martínez S, Genre F, Calvo-Alén J, Aurrecoechea E, Llorente I, Role of adiponectin in non-diabetic patients with rheumatoid arthritis undergoing anti-IL-6 therapy. Clin Exp Rheumatol. 2022;40(5):988-992. doi: 10.55563/clinex-prheumatol/p8nx80Pulito-Cueto V, Remuzgo-Martínez S, Genre F, Calvo-Alén J, Aurrecoechea E, Llorente I, Role of adiponectin in non-diabetic patients with rheumatoid arthritis undergoing anti-IL-6 therapy. Clin Exp Rheumatol. 2022;40(5):988-992. doi: 10.55563/clinex-prheumatol/p8nx80Virone A, Bastard JP, Fellahi S, Capeau J, Rouanet S, Sibilia J, et al. Comparative effect of tumour necrosis factor inhibitors versus other biological agents on cardiovascular risk-associated biomarkers in patients with rheumatoid arthritis. RMD Open. 2019;5(2): e000897. doi: 10.1136/rmdopen-2019-000897Virone A, Bastard JP, Fellahi S, Capeau J, Rouanet S, Sibilia J, et al. Comparative effect of tumour necrosis factor inhibitors versus other biological agents on cardiovascular risk-associated biomarkers in patients with rheumatoid arthritis. RMD Open. 2019;5(2): e000897. doi: 10.1136/rmdopen-2019-000897Choi IA, Sagawa A, Lee EY, Lee EB, Song YW. Tocilizumab increases body weight and serum adipokine levels in patients with rheumatoid arthritis independently of their treatment response: A retrospective cohort study. J Korean Med Sci. 2020;35(22):e155. doi: 10.3346/jkms.2020.35.e155Choi IA, Sagawa A, Lee EY, Lee EB, Song YW. Tocilizumab increases body weight and serum adipokine levels in patients with rheumatoid arthritis independently of their treatment response: A retrospective cohort study. J Korean Med Sci. 2020;35(22):e155. doi: 10.3346/jkms.2020.35.e155Novella-Navarro M, Genre F, Martínez-Feito A, Pulito-Cueto V, Plasencia-Rodríguez C, Balsa A. Obesity and adipose tissue cytokines in rheumatoid arthritis treated with IL-6 inhibitors: Does the route of administration matter? Clin Exp Rheumatol. 2023;41(7):1563-1564. doi: 10.55563/clinexprheumatol/4u63htNovella-Navarro M, Genre F, Martínez-Feito A, Pulito-Cueto V, Plasencia-Rodríguez C, Balsa A. Obesity and adipose tissue cytokines in rheumatoid arthritis treated with IL-6 inhibitors: Does the route of administration matter? Clin Exp Rheumatol. 2023;41(7):1563-1564. doi: 10.55563/clinexprheumatol/4u63htMakrilakis K, Fragiadaki K, Smith J, Sfikakis PP, Kitas GD. Interrelated reduction of chemerin and plasminogen activator inhibitor-1 serum levels in rheumatoid arthritis after interleukin-6 receptor blockade. Clin Rheumatol. 2015;34(3):419-427. doi: 10.1007/s10067-014-2704-1Makrilakis K, Fragiadaki K, Smith J, Sfikakis PP, Kitas GD. Interrelated reduction of chemerin and plasminogen activator inhibitor-1 serum levels in rheumatoid arthritis after interleukin-6 receptor blockade. Clin Rheumatol. 2015;34(3):419-427. doi: 10.1007/s10067-014-2704-1Chen DY, Chen YM, Hsieh TY, Hsieh CW, Lin CC, Lan JL. Significant effects of biologic therapy on lipid profiles and insulin resistance in patients with rheumatoid arthritis. Arthritis Res Ther. 2015;17(1):52. doi: 10.1186/s13075-015-0559-8Chen DY, Chen YM, Hsieh TY, Hsieh CW, Lin CC, Lan JL. Significant effects of biologic therapy on lipid profiles and insulin resistance in patients with rheumatoid arthritis. Arthritis Res Ther. 2015;17(1):52. doi: 10.1186/s13075-015-0559-8Стафеев ЮС, Юдаева АД, Мичурина СС, Меньшиков МЮ, Шестакова МВ, Парфёнова ЕВ. Взаимодействие воспаления и инсулиновой резистентности: перспективы иммунорегуляции как потенциального инструмента терапии сахарного диабета 2 типа. Сахарный диабет. 2023;26(2):192-202. doi: 10.14341/DM12982Stafeev IS, Yudaeva AD, Michurina SS, Menshikov MYu, Shestakova MV, Parfyonova YV. The interactions between inflammation and insulin resistance: Prospects of immunoregulation as a potential approach for the type 2 diabetes mellitus treatment. Diabetes mellitus. 2023;26(2):192-202 (In Russ.). doi: 10.14341/DM12982Paul SK, Montvida O, Best JH, Gale S, Pethö-Schramm A, Sarsour K. Association of biological antirheumatic therapy with risk for type 2 diabetes: A retrospective cohort study in incident rheumatoid arthritis. BMJ Open. 2021;11(6):e042246. doi: 10.1136/bmjopen-2020-042246Paul SK, Montvida O, Best JH, Gale S, Pethö-Schramm A, Sarsour K. Association of biological antirheumatic therapy with risk for type 2 diabetes: A retrospective cohort study in incident rheumatoid arthritis. BMJ Open. 2021;11(6):e042246. doi: 10.1136/bmjopen-2020-042246Greenbaum CJ, Serti E, Lambert K, Weiner LJ, Kanaparthi S, Lord S, et al.; ITN058AI EXTEND Study Team. IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes. JCI Insight. 2021;6(21):e150074. doi: 10.1172/jci.insight.150074Greenbaum CJ, Serti E, Lambert K, Weiner LJ, Kanaparthi S, Lord S, et al.; ITN058AI EXTEND Study Team. IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes. JCI Insight. 2021;6(21):e150074. doi: 10.1172/jci.insight.150074Ogata A, Morishima A, Hirano T, Hishitani Y, Hagihara K, Shima Y, et al. Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab. Ann Rheum Dis. 2011;70(6):1164-1165. doi: 10.1136/ard.2010.132845Ogata A, Morishima A, Hirano T, Hishitani Y, Hagihara K, Shima Y, et al. Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab. Ann Rheum Dis. 2011;70(6):1164-1165. doi: 10.1136/ard.2010.132845Otsuka Y, Kiyohara C, Kashiwado Y, Sawabe T, Nagano S, Kimoto Y, et al. Effects of tumor necrosis factor inhibitors and tocilizumab on the glycosylated hemoglobin levels in patients with rheumatoid arthritis; an observational study. PLoS One. 2018;13(4):e0196368. doi: 10.1371/journal.pone.0196368Otsuka Y, Kiyohara C, Kashiwado Y, Sawabe T, Nagano S, Kimoto Y, et al. Effects of tumor necrosis factor inhibitors and tocilizumab on the glycosylated hemoglobin levels in patients with rheumatoid arthritis; an observational study. PLoS One. 2018;13(4):e0196368. doi: 10.1371/journal.pone.0196368Genovese MC, Burmester GR, Hagino O, Thangavelu K, Iglesias-Rodriguez M, John GS, et al. Interleukin-6 receptor blockade or TNFα inhibition for reducing glycaemia in patients with RA and diabetes: Post hoc analyses of three randomised, controlled trials. Arthritis Res Ther. 2020;22(1):206. doi: 10.1186/s13075-020-02229-5Genovese MC, Burmester GR, Hagino O, Thangavelu K, Iglesias-Rodriguez M, John GS, et al. Interleukin-6 receptor blockade or TNFα inhibition for reducing glycaemia in patients with RA and diabetes: Post hoc analyses of three randomised, controlled trials. Arthritis Res Ther. 2020;22(1):206. doi: 10.1186/s13075-020-02229-5Patel NJ, Tozzo V, Higgins JM, Stone JH. The effects of daily prednisone and tocilizumab on hemoglobin A1c during the treatment of giant cell arteritis. Arthritis Rheumatol. 2023;75(4):586-594. doi: 10.1002/art.42405Patel NJ, Tozzo V, Higgins JM, Stone JH. The effects of daily prednisone and tocilizumab on hemoglobin A1c during the treatment of giant cell arteritis. Arthritis Rheumatol. 2023;75(4):586-594. doi: 10.1002/art.42405Castañeda S, Remuzgo-Martínez S, López-Mejías R, Genre F, Calvo-Alén J, Llorente I, et al. Rapid beneficial effect of the IL-6 receptor blockade on insulin resistance and insulin sensitivity in non-diabetic patients with rheumatoid arthritis. Clin Exp Rheumatol. 2019;37(3):465-473.Castañeda S, Remuzgo-Martínez S, López-Mejías R, Genre F, Calvo-Alén J, Llorente I, et al. Rapid beneficial effect of the IL-6 receptor blockade on insulin resistance and insulin sensitivity in non-diabetic patients with rheumatoid arthritis. Clin Exp Rheumatol. 2019;37(3):465-473.Finucane FM, Luan J, Wareham NJ, Sharp SJ, O’Rahilly S, Balkau B, et al.; on behalf of the European Group for the Study of Insulin Resistance: Relationship between Insulin Sensitivity and Cardiovascular Disease Risk Study Group. Correlation of the leptin:adiponectin ratio with measures of insulin resistance in non-diabetic individuals. Diabetologia. 2009;52(11):2345-2349. doi: 10.1007/s00125-009-1508-3Finucane FM, Luan J, Wareham NJ, Sharp SJ, O’Rahilly S, Balkau B, et al.; on behalf of the European Group for the Study of Insulin Resistance: Relationship between Insulin Sensitivity and Cardiovascular Disease Risk Study Group. Correlation of the leptin:adiponectin ratio with measures of insulin resistance in non-diabetic individuals. Diabetologia. 2009;52(11):2345-2349. doi: 10.1007/s00125-009-1508-3Kang Y, Park HJ, Kang MI, Lee HS, Lee SW, Lee SK, et al. Adipokines, inflammation, insulin resistance, and carotid atherosclerosis in patients with rheumatoid arthritis. Arthritis Res Ther. 2013;15(6):R194. doi: 10.1186/ar4384Kang Y, Park HJ, Kang MI, Lee HS, Lee SW, Lee SK, et al. Adipokines, inflammation, insulin resistance, and carotid atherosclerosis in patients with rheumatoid arthritis. Arthritis Res Ther. 2013;15(6):R194. doi: 10.1186/ar4384Ellingsgaard H, Seelig E, Timper K, Coslovsky M, Soederlund L, Lyngbaek MP, et al. GLP-1 secretion is regulated by IL-6 signalling: a randomised, placebo-controlled study. Diabetologia. 2020;63(2):362-373. doi: 10.1007/s00125-019-05045-yEllingsgaard H, Seelig E, Timper K, Coslovsky M, Soederlund L, Lyngbaek MP, et al. GLP-1 secretion is regulated by IL-6 signalling: a randomised, placebo-controlled study. Diabetologia. 2020;63(2):362-373. doi: 10.1007/s00125-019-05045-y

The authors declare that there are no conflicts of interest present.